Catalent Pharma Solutions, noted that its partner, Lexicon Pharmaceuticals, has received US Food and Drug Administration approval for Xermelo (telotristat ethyl) 250 mg, an orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Catalent has been working in partnership with Lexicon since 2007 to develop the drug formulation and will be manufacturing the drug for commercial supply.

Catalent undertook development and manufacture of the drug at its 450,000-square-foot facility in Kansas City, Missouri, where the company provides formulation development ,analytical testing, clinical- and commercial-scale manufacturing, and packaging of various oral dose forms.

Source: Catalent Pharma Solutions